ConXn: Phase II data; Phase II/III

CNCT published in the Annals of Internal Medicine data from a 68-patient U.S. Phase II trial showing a statistically significant improvement in Modified Rodnan Skin Score at 4, 12 and 24 weeks in patients given a 25 ? g/kg/day continuous subcutaneous infusion of ConXn compared to placebo (p=0.021 at 4 weeks, p<0.001 at 12 weeks and p=0.040 at 24 weeks). Treatment with 100 ? g/kg/day of ConXn did not show statistically significant improvement, which CNCT said was consistent with the in vitro dose response properties of the anti-fibrotic compound. The trial also showed positive trends on secondary end points including lung function, oral aperture, hand extension, and measures of disability. ...